Stephens Investment Management Group LLC Has $8.21 Million Stock Holdings in AxoGen, Inc. $AXGN

Stephens Investment Management Group LLC raised its stake in AxoGen, Inc. (NASDAQ:AXGN) by 60.9% in the first quarter, Holdings Channel reports. The firm owned 247,886 shares of the medical equipment provider’s stock after acquiring an additional 93,801 shares during the quarter. Stephens Investment Management Group LLC’s holdings in AxoGen were worth $8,212,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Royal Bank of Canada lifted its stake in AxoGen by 14.2% in the 1st quarter. Royal Bank of Canada now owns 38,043 shares of the medical equipment provider’s stock valued at $704,000 after purchasing an additional 4,723 shares during the last quarter. AQR Capital Management LLC boosted its stake in shares of AxoGen by 45.3% during the 1st quarter. AQR Capital Management LLC now owns 23,917 shares of the medical equipment provider’s stock worth $442,000 after acquiring an additional 7,453 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of AxoGen by 4.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 25,185 shares of the medical equipment provider’s stock worth $466,000 after acquiring an additional 1,057 shares during the period. Jones Financial Companies Lllp raised its stake in AxoGen by 104,810.0% in the 1st quarter. Jones Financial Companies Lllp now owns 10,491 shares of the medical equipment provider’s stock valued at $194,000 after acquiring an additional 10,481 shares during the period. Finally, JPMorgan Chase & Co. lifted its holdings in AxoGen by 37.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 379,070 shares of the medical equipment provider’s stock valued at $4,113,000 after purchasing an additional 103,072 shares during the last quarter. Institutional investors own 80.29% of the company’s stock.

Wall Street Analysts Forecast Growth

AXGN has been the topic of several research reports. Zacks Research upgraded shares of AxoGen from a “strong sell” rating to a “hold” rating in a report on Friday, May 29th. Citizens Jmp upped their price target on shares of AxoGen from $42.00 to $50.00 and gave the company a “market outperform” rating in a research note on Wednesday, April 29th. HC Wainwright raised their price objective on shares of AxoGen from $39.00 to $50.00 and gave the stock a “buy” rating in a research report on Wednesday, April 29th. Weiss Ratings restated a “sell (d-)” rating on shares of AxoGen in a report on Friday, May 29th. Finally, Raymond James Financial reissued an “outperform” rating and set a $48.00 price target on shares of AxoGen in a report on Wednesday, April 29th. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $46.50.

Insider Activity

In other AxoGen news, Director Kathy Johnson Weiler sold 16,344 shares of the stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $44.09, for a total transaction of $720,606.96. Following the sale, the director directly owned 16,344 shares in the company, valued at $720,606.96. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director John Johnson sold 11,050 shares of the firm’s stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $43.26, for a total transaction of $478,023.00. Following the completion of the transaction, the director directly owned 11,050 shares in the company, valued at approximately $478,023. This represents a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 29,041 shares of company stock worth $1,268,792. 2.44% of the stock is currently owned by company insiders.

AxoGen Stock Performance

NASDAQ AXGN opened at $45.89 on Monday. The firm has a 50-day moving average price of $42.32 and a two-hundred day moving average price of $36.17. AxoGen, Inc. has a 12-month low of $10.71 and a 12-month high of $46.95. The company has a market capitalization of $2.44 billion, a P/E ratio of -71.70 and a beta of 1.09. The company has a quick ratio of 5.33, a current ratio of 7.10 and a debt-to-equity ratio of 0.08.

AxoGen (NASDAQ:AXGN) last released its quarterly earnings results on Tuesday, April 28th. The medical equipment provider reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.05). The business had revenue of $61.46 million during the quarter, compared to analyst estimates of $57.85 million. AxoGen had a negative net margin of 13.21% and a negative return on equity of 9.63%. Analysts anticipate that AxoGen, Inc. will post -0.37 earnings per share for the current year.

AxoGen Profile

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.